Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).

A Prospective, Randomized, Investigator-blind, Controlled, Clinical Study of Phase III on the Efficacy and Tolerability of hMG-IBSA (IBSA) vs Menopur (Ferring) Administered s.c. in Women Undergoing COH in an ART Programme (IVF)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00335894

Enrollment

144

Registered

2006-06-12

Start date

2005-05-31

Completion date

2009-03-31

Last updated

2010-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Infertility, IVF, ART, hMG

Brief summary

Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and the other the reference drug hMG (Menopur, Ferring Pharmaceuticals, Inc.).

Detailed description

The purpose of the study is to evaluate the clinical efficacy and general tolerability of two different subcutaneous hMG preparations (hMG-IBSA, IBSA vs Menopur, Ferring Pharmaceuticals, Inc.) when administered to patients undergoing controlled ovarian stimulation for IVF.

Interventions

DRUGhMG-IBSA

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 36 Years

Healthy volunteers

Inclusion criteria

* Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic sperm injection) and with the following characteristics: * Voluntary given informed consent to study participation in writing encompassing consent to data recording and verification procedures; * \> 18/= and \< 37 years old; * BMI between 18 and 28 kg/m2; * Less than 3 previous completed IVF cycles; * Basal FSH level less than 10 IU/L once within 6 months prior to the study; * Within 12 month of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, or sonohysterogram, or hysteroscopic examination or TVUS; * Normal or clinically insignificant haematology and blood chemistry values.

Exclusion criteria

* Primary ovarian failure or women known as poor responders; * Signs of PCO, according to the Rotterdam Criteria; * At least one ovary inaccessible for oocyte retrieval; * One or more ovarian cysts \> 10 mm; * Hydrosalpinx that have not been surgically removed or ligated; * Stage III or IV endometriosis; * Patients affected by pathologies associated with any contraindication of being pregnant; * Hypersensitivity to the study medication; * Abnormal bleeding of undetermined origin; * Uncontrolled thyroid or adrenal dysfunction; * Neoplasias; * PAP smear III within the last 2 years; * Severe impairment of the renal and/or hepatic functions; * Lactation; * Hyperprolactinaemia; * Participation in a concurrent clinical trial or in another trial within the past four weeks; * Use of concomitant medication that might interfere with study evaluations.

Design outcomes

Primary

Measure	Time frame
total number of oocytes retrieved 34 - 36 hours after hCG administration.	—

Secondary

Measure	Time frame
Total dose of hMG (IU); number of days of hMG stimulation and stimulation duration; cancellation rate with reasons; 17β-estradiol (E2) serum concentration; number of follicles >16 mm.	—
number of mature oocytes and inseminated oocytes; fertilization rate.	—
embryo score; number of transferred embryos; implantation rate, number of transferred embryos; clinical pregnancy rate	—
Tolerability evaluation	—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026